Quinoline derivatives which are 5-hydroxytryptamine antagonists
Patent 4435405 Issued on March 6, 1984. Estimated Expiration Date: 
May 26, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
May 26, 2002. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent References Re16394 1572768 1860286 Heterocyclic compounds Patent #: 4343805 Inventors
AssigneeApplicationNo. 06/382116 filed on 05/26/1982US Classes:514/312, Chalcogen attached directly to the six-membered hetero ring by nonionic bonding546/157, Chalcogen attached directly at 2-position by nonionic bonding546/167, Unsaturated hetero ring attached directly to the quinoline ring system by nonionic bonding546/173, Unsaturated carbocyclic ring attached directly to the quinoline ring system by nonionic bonding (e.g., quinophthalones, etc.)546/180Halogen or nitro attached directly or indirectly to the quinoline ring system by nonionic bondingExaminersPrimary: Daus, Donald G.Assistant: Rivers, Diana G. Attorney, Agent or FirmInternational ClassesC07C 233/00 (20060101)C07C 233/11 (20060101) C07D 211/42 (20060101) C07D 211/00 (20060101) C07D 215/00 (20060101) C07D 215/18 (20060101) C07D 215/36 (20060101) C07D 277/00 (20060101) C07F 7/08 (20060101) C07F 7/00 (20060101) C07D 277/28 (20060101) C07D 333/00 (20060101) C07D 333/24 (20060101) Foreign Application Priority Data1981-06-09 GBAbstractCompounds of the formula: ##STR1## wherein A stands for the radical --(CH2)2 -- which may bear one or two defined substituents; R1 stands for a (3-4C) alkyl or cyclopropyl radical, or a phenyl radical which may optionally bear one or two defined substituents, or a heteroaryl radical of five or six ring atoms which may optionally bear a (1-3C)alkyl substituent; R2 and R3 stand for hydrogen or a (1-2C)alkyl radical, or R2 stands for a (2-4C)alkylene radical which is linked to one of the carbon atoms forming the two-carbon-atom-backbone of A so as to form, together with the adjacent nitrogen atom, a pyrrolidinyl or piperidyl radical; and one of R4 and R5 stands for hydrogen, and the other stands for hydrogen, a halogen atom or a (1-3C)alkyl or (1-3C)alkoxy radical; and acid-addition salts thereof. Processes for the manufacture of said compounds. Pharmaceutical compositions comprising one of said compounds and a pharmaceutical diluent or carrier. The compounds are 5-hydroxytryptamine antagonists.Other References
|
| ||||||||||||||
